Nurix Therapeutics (NASDAQ:NRIX) Now Covered by BMO Capital Markets

Analysts at BMO Capital Markets began coverage on shares of Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) in a report issued on Friday, MarketBeat reports. The firm set an "outperform" rating and a $35.00 price target on the stock. BMO Capital Markets' price target suggests a potential upside of 63.78% from the company's current price.

A number of other research firms have also weighed in on NRIX. Needham & Company LLC restated a "buy" rating and issued a $29.00 target price on shares of Nurix Therapeutics in a report on Wednesday, November 6th. HC Wainwright raised their price objective on Nurix Therapeutics from $26.00 to $30.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Oppenheimer upped their target price on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 4th. Stephens reissued an "overweight" rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Monday, October 14th. Finally, Robert W. Baird began coverage on shares of Nurix Therapeutics in a research report on Friday, September 6th. They issued an "outperform" rating and a $26.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $29.75.

Nurix Therapeutics Stock Performance

NRIX stock traded up $1.31 during midday trading on Friday, reaching $21.37. 1,021,668 shares of the company's stock traded hands, compared to its average volume of 863,137. Nurix Therapeutics has a 52 week low of $7.65 and a 52 week high of $29.56. The firm's fifty day moving average price is $23.79 and its 200-day moving average price is $21.90.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Friday, October 11th. The company reported ($0.67) EPS for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. The company had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. Analysts forecast that Nurix Therapeutics will post -2.81 EPS for the current fiscal year.

Insider Activity

In related news, insider Christine Ring sold 5,760 shares of the firm's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total value of $128,044.80. Following the completion of the transaction, the insider now directly owns 24,592 shares of the company's stock, valued at approximately $546,680.16. This trade represents a 18.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 3,546 shares of the business's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $24.28, for a total transaction of $86,096.88. Following the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at $818,818.72. The trade was a 9.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,401 shares of company stock valued at $437,453 in the last 90 days. Insiders own 7.20% of the company's stock.

Institutional Trading of Nurix Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NRIX. Amalgamated Bank grew its holdings in Nurix Therapeutics by 30.6% during the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company's stock valued at $49,000 after buying an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Nurix Therapeutics by 31.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock valued at $54,000 after acquiring an additional 559 shares in the last quarter. Quest Partners LLC increased its holdings in Nurix Therapeutics by 21.3% during the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company's stock worth $168,000 after acquiring an additional 1,312 shares during the period. ClariVest Asset Management LLC lifted its stake in Nurix Therapeutics by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company's stock worth $1,318,000 after purchasing an additional 1,766 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its stake in Nurix Therapeutics by 8.4% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 30,024 shares of the company's stock worth $675,000 after purchasing an additional 2,329 shares in the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.